|
AMASS version 3.0
- Released on 30 April 2024
Description:
- Add Annex C: Cluster signals. This annex shows potential clusters of patients with AMR infection identified using the SaTScan (www.satscan.org).
- Leave processed (i.e. de-duplicated and/or merged) data files for any further analysis and internal use after using the AMASS.;
- Enterococcus faecalis and E. faecium have been explicitly included in the pathogens under the survey
- Add a few antibiotics in the list of antibiotics for a few pathogens under the survey;
- Improve algorithms for supporting more several date formats, data file translation, a larger data se , and Data_verification_logfile report;
- Used only Python rather than R + Python (as used in the AMASSv2.0);
- Set a default config for infection origin stratification by allowing a specimen collected two calendar days before the hospital admission date and one day after the hospital discharge date into consideration. This config supports the real-world setting that several hospitals in LMICs (particularly Thailand) have patients stay in the hospital (e.g. at ER) due to many limitations before official admissions can be made.;
- Improve the algorithm to include patients who were not yet discharged from the hospital (i.e. having no discharge dates yet) in the analysis by truncating at the last date of specimen date in the whole data set (usually at the end of the year [e.g. 31 Dec] or the survey period). This algorithm improve the ‘bed-days at risk’ and ‘bed-days at risk for hospital-origin infection’ to be precisely estimated.
AMASS version 3.0 (BETA) Build 3026
- Released on 10 January 2024
Description:
- Support display Thai charectors.
- Add Table S10A and S10B to display list of data values and variable recorded for "ward" in microbiology data file and hospital admission data file.
AMASS version 3.0 (BETA) Build 3022
- Released on 4 December 2023
Description:
- Add “Annex C: Cluster signals”. This supplementary report shows the information of potential clusters which are identified using the SatScan (www.satscan.org).
- Add processed data files in the folder “Report_with_patient_identifiers” so that users can use the processed data file (e.g. deduplicated and merged data files for each AMR pathogen) for any further analysis on internal use.
- Enterococcus faecalis and E. faecium were explicitly included in the pathogens under the survey (while Enterococcus spp. was used in the AMASS version 2.0)
- Add a few antibiotics in the list of antibiotics for a few pathogens under the survey.
- Use only Python rather than R + Python (as used in the AMASS version 2.0).
- Include patients who have missing discharge dates in the analysis by truncating the day at risk using the last date of specimen date in the data set (e.g. a patient who was admitted on 30 Dec 2023, had blood specimen collected for culture on 31 Dec 2023, and were still in the hospital on 10 Jan 2024. Then, the microbiology data file and hospital admission date file were exported on 10 Jan 2024 for the data of year 2023 [specimen dates and hospital admission dates from 1 Jan 2023 to 31 Jan 2023]. This patient would be included in the analysis, assuming that the days at risk of BSI was from 30 Dec to 31 Dec 2023, and the specimen collected on 31 Dec 2023 would be included in the analysis. In the AMASS version 2.0, this patient would not be included in the analysis as the code for truncation among patients who were not discharged was not included in the AMASS version 2.0).
AMASS version 2.0
- Released on 16 November 2022
Description:
This version fixes a typo in the R code that caused inaccurate estimations of the proportion of patients with non-susceptible isolates against levofloxacin and carbapenem drugs. In addition, this version also allows users to choose whether an organism included for the AMR Surveillance Report is Acinetobacter spp. or Acinetobacter baumanii.
- Released on 16 May 2022
Description:
AMASS v2.0 is implemented from AMASSplus that was released on 25 Mar 2021. AMASS v2.0 additionally generates reports on notifiable bacterial diseases in Annex A and on data indicators (including proportion of contaminants and discordant AST results) in Annex B. AMASS version 2.0 also separately generates Supplementary data indictors report to support users to check and validate records at the local level. For any queries about AMASS, please contact AMASS team (amass@tropmedres.ac).
AMASSplus
- Released on 25 Mar 2021
Description:
The AMASSplus application is an extension of AMASS Version 1.1 that was released on 12 January 2021. AMASSplus has an additional report (page 38-40) on selected notifiable bacterial diseases. For implementation of AMASSplus at your hospitals in Thailand, please contact Preeyarach Klaytong (preeyarach@tropmedres.ac) and Viriya Hantrakun (viriya@tropmedres.ac).
AMASS version 1.1
- Released on 12 Jan 2021
Description:
This is a version with bugs fixed. AMASS 1.1 fixes a typo in the R codes of the AMASS 1.0 that caused inaccurate estimations of the proportion of non-susceptible isolates of E. coli and K. pneumoniae for ampicillin (page 9-10 and page 18-21 in the AMR surveillance report).
Version Beta 12102019
- Released on 12 Oct 2019
Description:
This is a beta version with new sections added, typos corrected and bug fixed from Version_Beta_26022019. In this version, there are 6 completed sections. The sections are [1] Data overview; [2] Isolated-based surveillance report without stratification by infection origin; [3] Isolated-based surveillance report with stratification by infection origin; [4] Sample-based surveillance report without stratification by infection origin; [5] Sample-based surveillance report with stratification by infection origin; and [6] Mortality in AMR and antimicrobial-susceptible infections.
Version Beta 26022019
- Released on 16 Feb 2019
Description:
This is the first released version of AMASS that contained 4 main sections. The sections are [1] General demographic data; [2] Isolated-based surveillance report without stratification by infection origin; [3] Isolated-based surveillance report with stratification by infection origin; and [5] Mortality in AMR and antimicrobial-susceptible infections. Please note that in this version, Section [4] on Sample-based surveillance report was under development (incomplete).
|